---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-098049"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:49:17.981200+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma enters new employment agreement with CEO Prashant Kohli

## Summary
- Annual base salary of $500,000 and eligible for discretionary bonus up to 50% of base.
- Severance of 12 months' base salary if terminated without cause (including after change of control).
- Subject to board approval, may receive stock options under the company's equity incentive plan.
- 12-month non-compete and non-solicitation clauses; standard benefits and vacation included.

## SEC filing metadata
- accession: 0000950170-24-098049
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017024098049/0000950170-24-098049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017024098049/acst-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-098049
- JSON: https://secwatch.observer/filing/0000950170-24-098049.json
- Plain text: https://secwatch.observer/filing/0000950170-24-098049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.